BIO19208-T1

USE OF CD9 AS A BIOMARKER AND AS A BIOTARGET IN GLOMERULONEPHRITIS

The mechanisms driving the development of extracapillary lesions in focal segmental glomerulosclerosis (FSGS) and crescentic glomerulonephritis (CGN) remain poorly understood. A key question is how parietal epithelial cells (PECs) invade glomerular capillaries, thereby promoting injury and kidney failure. Here the inventors show that expression of the tetraspanin CD9 increases markedly in PECs in mouse models of CGN and FSGS, and in kidneys from individuals diagnosed with these diseases. Cd9 gene targeting in PECs prevents glomerular damage in CGN and FSGS mouse models. Mechanistically, CD9 deficiency prevents the oriented migration of PECs into the glomerular tuft and their acquisition of CD44 and Beta 1 integrin expression. These findings highlight a critical role for de novo expression of CD9 as a common pathogenic switch driving the PEC phenotype in CGN and FSGS, while offering a potential therapeutic avenue to treat these conditions. Accordingly CD9 represents a reliable biomarker and as well as a biotargets in glomerulonephritis.


Keywords : -
Patent Application number : 19305721.3
Patent Application date : 2019-06-04
Multidisciplinary field : -
Technology/Engineering : -
Technological Platform : -
Rare disease : Yes
Second indication : -
Inventors : -
Publications :
  • Nat Commun. 2019 Jul 24;10(1):3303. doi: 10.1038/s41467-019-11013-2.

Related offers


The 10 Last viewed

You haven't seen any form yet.